NYSE:LHHealthcare
Does Labcorp’s New Oncology Genetics Initiatives Shift the Precision Medicine Narrative For Labcorp (LH)?
In late May 2026, Labcorp announced a collaboration with the Alliance for Clinical Trials in Oncology on a nationwide colorectal cancer genetics trial and, separately, expanded its DPYD genotyping test to help identify patients at higher risk of severe side effects from fluoropyrimidine chemotherapy.
Together, these moves underscore Labcorp’s focus on genetics-driven oncology care, positioning its Invitae-based testing and pharmacogenomics portfolio at the center of evolving cancer treatment...